ABSTRACT:
The aim of the present study was to develop a Cisplatin loaded NLCS to enhanced and effective delivery of drug to the skin cancer. NLCS bearing Cisplatin were prepared by emulsification solvent diffusion method. The formulated NLCS were characterised for average particle size, polydispersity index (PDI) Zeta potential, entrapment efficiency and in vitro drug release study. The prepared formulations were studied for its in vitro cell line and cell uptake study. It was revealed that the average size of NLCS was found 172.2±3.2, PDI was 0.135, % entrapment efficiency was found 68.9±2.04 and Zeta potential was found -15.3±1.3. In-vitro release determined by Frenz diffusion cell was found 63.7±2.8% after 72 hr. MTT assay shows that Cisplatin loaded NLCS were giving more cytotoxity as compare to plain drug. The cell uptake study was found enhanced uptake of FITC loaded NLCS in comparison to plain FITC. Cisplatin and Cisplatin loaded NLCS showed 22.3±1.2 and 32.8±0.9 growth inhibition respectively after 48h upon incubation at 0.5 µg/mL concentration (p<0.05). The result of the studies was concluded that NLCS can be use as impending drug delivery system which may enhance the drug uptake and maintain the drug level for longer period of time and it is potential carrier system which can be use for the treatment of skin diseases like cancer.
Cite this article:
Arti Majumdar, Nidhi Dubey, Nitin Dubey. Cisplatin loaded Nano Lipid Carriers for the Treatment of Skin Cancer. Research J. Pharm. and Tech 2020; 13(3): 1483-1488. doi: 10.5958/0974-360X.2020.00270.X
Cite(Electronic):
Arti Majumdar, Nidhi Dubey, Nitin Dubey. Cisplatin loaded Nano Lipid Carriers for the Treatment of Skin Cancer. Research J. Pharm. and Tech 2020; 13(3): 1483-1488. doi: 10.5958/0974-360X.2020.00270.X Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2020-13-3-75
REFERENCES:
1.
Ghadge Ojaswi,
Nadar Divya, Parmar Digna. Melanoma and its Drug Targets. Research J. Pharm.
and Tech. 2016; 9(5): 562-570.
2.
Rayate Yogita,
Shaikh Samina, Sakhare Pooja, Gandhi Jyotsana. Review on Skin Cancer. Asian J.
Res. Pharm. Sci. 2018; 8(2):100-106.
3.
Tammineni Sreelatha,
M. V. Subramanyam, M. N. Giri Prasad. A Survey work on Early Detection methods
of Melanoma Skin Cancer. Research J. Pharm. and Tech. 2019; 12(5):2589-2596.
4.
Majumdar A, Dubey
N, Malviya N. Nanostructure lipid carriers: a promising tool for the drug delivery
in the treatment of skin cancer. Asian J Pharm Clin Res. 2019; 5: 15-26
5.
Akila Victor,
Muhammad Rukunuddin Ghalib. Detection of Skin Cancer Cells –A Review. Research
J. Pharm. and Tech 2017; 10(11): 4093-4098.
6.
Chan DA, Giaccia AJ. Hypoxia, gene expression, and metastasis. Cancer
Metastasis Rev. 2007; 26:333–339.
7.
Gupta AK, Bharadwaj M, Mehrotra R. Skin Cancer Concerns in People of Color: Risk
Factors and Prevention. Asian Pac J Cancer Prev. 2016;
17(12): 5257–5264.
8.
Anish Chandy,
Dheeraj Ahirwar. Ex-Vivo Evaluation of Enteric Coated Microparticles Containing
an Anti-Cancer Drug. Research J. Pharm. and Tech 2018; 11(8): 3509-3513.
9.
Ramandeep Singh, Ashutosh Upadhayay, M. K.
Kale. Effect of Liposomes as a carrier on Pharmacokinetics of Cisplatin. Research
J. Pharm. and Tech 2018; 11(11): 5073-5077.
10.
Radha Krishna
Kollipara, Vyshnavi Tallapaneni, Bharat Kumar Reddy Sanapalli, Vinoth Kumar G,
Veera Venkata Satyanarayana Reddy Karri. Curcumin Loaded Ethosomal Vesicular
Drug Delivery System for the Treatment of Melanoma Skin Cancer.
11. Shao Z, Shao J, Tan B, et al. Targeted lung cancer therapy:
preparation and optimization of transferrin-decorated nanostructured lipid
carriers as novel nanomedicine for co-delivery of anticancer drugs and
DNA. Int J Nanomedicine. 2015; 10:1223.
12. Majumdar A, Dubey N.
Formulation of Paclitaxel loaded nanostructured lipid carriers to study the
effect of concentration of liquid lipids on drug release. Journal of Drug Delivey and Therapeutics. 2017; 7(7): 26-28.
13. Tupal A, Sabzichi M, Ramezani F, et al. Dermal
delivery of doxorubicin-loaded solid lipid nanoparticles for the treatment of
skin cancer. J Microencapsul. 2016; 33:372–80.
14. Kong G, Barun RD and Dewhirst MW. Hyperthermia enables
tumor specific nanopartic1es delivery and effect of particle size. Cancer Res.
2000; 60: 4440-4446.
15. Li Y, Ogris M, Wagner E, Pelisek L, Ruffer M.
Nanoparticles bearing polyethyleneglycol-coupled transferrin as gene carriers:
preparation and in vitro evaluation. International Journal of Pharmaceutics.
2003; 259: 93-101.
16. Lu Y, Low PS. Folate targeting of haptens to cancer
cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer
Immunol. Immunother. 2002; 51: 153-162.
17. Selvamuthukumar S, Velmurugan R. Nanostructured lipid
carriers: a potential drug carrier for cancer chemotherapy. Lipids Health
Dise. 2012; 11: 1.
18. Satish Shilpi, Vishnoo Dayal Vimal, and Vandana
Soni. “Assessment of
lactoferrin-conjugated solid lipid nanoparticles for efficient targeting to the
lung. Prog Biomater. 2015; 4: 55–63.
19. Patel
K, Solanki N, Solanki S. Nanostructured lipid carrier-a novel drug
delivery. J Pharm Sci Bioscientific Res. 2015;
5: 385-92.
20. Gupta
Y, Jain A, Jain SK. Transferrin-conjugated solid lipid nanoparticles for
enhanced delivery of quinine dihydrochloride to the brain. J Pharm Pharmacol. 2007;
59: 1-6.
21. Khan AW, Kotta S, Ansari SH, Sharma,
RK, Kumar A, and Javed A. Formulation development, optimization
and evaluation of aloe vera gel for wound healing. Pharmacogn
Mag. 2013; 9: S6–S10.
22. S. Bornare, R. B. Saudagar. Nanostructured Lipid
Carrier (NLC): A Modern Approach for Transdermal Drug Delivery. Research J.
Pharm. and Tech. 2017; 10(8): 2784-2792.
23. Tristiana Erawati, Dewi Melani Hariyadi, Noorma
Rosita, Tutiek Purwanti. The Anti-inflammatory Activity of p-methoxycinnamic
acid (PMCA) in the Nanostructured lipid carrier (NLC) system using combinations
of solid lipid, beeswax-oleum cacao and liquid lipid, Virgin Coconut oil (VCO).
Research J. Pharm. and Tech 2019; 12(8): 3619-3625.
24. Vinodkumar Mugada, Jyothipriya Hanumanthu, Juhi
Shagufa, Sosamma Iype, Sowmya Yerlapati. Assessment of Ototoxicity and
Nephrotoxicity in patients receiving weekly Cisplatin Chemotherapy: A
Prospective Observational Study. Research J. Pharm. and Tech. 2019;
12(4):1922-1926.